Growth Metrics

Novavax (NVAX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $263.5 million.

  • Novavax's Other Non-Current Liabilities fell 1738.2% to $263.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.5 million, marking a year-over-year decrease of 1738.2%. This contributed to the annual value of $359.6 million for FY2024, which is 98546.33% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Other Non-Current Liabilities is $263.5 million, which was down 1738.2% from $287.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Other Non-Current Liabilities registered a high of $359.6 million during Q4 2024, and its lowest value of $20.6 million during Q2 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $66.8 million (2022), whereas its average is $146.8 million.
  • In the last 5 years, Novavax's Other Non-Current Liabilities plummeted by 6216.25% in 2023 and then skyrocketed by 98546.33% in 2024.
  • Over the past 5 years, Novavax's Other Non-Current Liabilities (Quarter) stood at $42.1 million in 2021, then skyrocketed by 32.23% to $55.7 million in 2022, then crashed by 40.52% to $33.1 million in 2023, then soared by 985.46% to $359.6 million in 2024, then dropped by 26.73% to $263.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $263.5 million for Q3 2025, versus $287.6 million for Q2 2025 and $313.7 million for Q1 2025.